Literature DB >> 21484378

Molecular imaging in patients with mood disorders: a review of PET findings.

Qiaozhen Chen1, Weibo Liu, Huichun Li, Hong Zhang, Mei Tian.   

Abstract

Mood disorders are chronic, recurrent psychiatric disorders with high morbidity rates that cause severe disability. Researchers have used molecular imaging extensively in studies of mood disorders. In this article, we concisely and selectively review the major findings of positron emission tomography studies of patients with mood disorders. Specifically, we describe findings from cerebral blood flow, cerebral glucose/oxygen metabolism, and radioligand studies in both cross-sectional and longitudinal investigations. Patients with mood disorders have mood-correlated regional metabolism changes and molecular abnormalities in several neurotransmitter systems. Although the findings of these studies are not completely consistent and confounding factors, including drug effects and specific methodology, should be strictly controlled, these results reveal the pathophysiology of mood disorders and aid the development of novel treatment approaches for mood disorders. Future positron emission tomography research will benefit greatly from the development of better radioligands to simultaneously identify multiple neurotransmitter systems in the specific brain region and the integration of more detecting methods in specifying the neurobiological predictors of treatment response in patients with mood disorders. Understanding the molecular mechanisms in underlying mood disorders will result in aetiological diagnosis and individualization of treatment of these disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21484378     DOI: 10.1007/s00259-011-1779-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  79 in total

1.  Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study.

Authors:  Jeffrey H Meyer; Heather E McNeely; Sandra Sagrati; Anahita Boovariwala; Krystle Martin; N Paul L G Verhoeff; Alan A Wilson; Sylvain Houle
Journal:  Am J Psychiatry       Date:  2006-09       Impact factor: 18.112

2.  Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder.

Authors:  Dara M Cannon; Masanori Ichise; Denise Rollis; Jacqueline M Klaver; Shilpa K Gandhi; Dennis S Charney; Husseini K Manji; Wayne C Drevets
Journal:  Biol Psychiatry       Date:  2007-08-02       Impact factor: 13.382

3.  Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder.

Authors:  Dara M Cannon; Richard E Carson; Allison C Nugent; William C Eckelman; Dale O Kiesewetter; Joan Williams; Denise Rollis; Michele Drevets; Shilpa Gandhi; Gerardo Solorio; Wayne C Drevets
Journal:  Arch Gen Psychiatry       Date:  2006-07

4.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

5.  Serotonin 1A receptor binding and treatment response in late-life depression.

Authors:  Carolyn Cidis Meltzer; Julie C Price; Chester A Mathis; Meryl A Butters; Scott K Ziolko; Eydie Moses-Kolko; Sati Mazumdar; Benoit H Mulsant; Patricia R Houck; Brian J Lopresti; Lisa A Weissfeld; Charles F Reynolds
Journal:  Neuropsychopharmacology       Date:  2004-12       Impact factor: 7.853

6.  Decreased prefrontal, anterior cingulate, insula, and ventral striatal metabolism in medication-free depressed outpatients with bipolar disorder.

Authors:  John O Brooks; Po W Wang; Julie C Bonner; Allyson C Rosen; Jennifer C Hoblyn; Shelley J Hill; Terence A Ketter
Journal:  J Psychiatr Res       Date:  2008-06-25       Impact factor: 4.791

7.  The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine.

Authors:  D Attar-Lévy; J L Martinot; J Blin; M H Dao-Castellana; C Crouzel; B Mazoyer; M F Poirier; M C Bourdel; N Aymard; A Syrota; A Féline
Journal:  Biol Psychiatry       Date:  1999-01-15       Impact factor: 13.382

8.  5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study.

Authors:  Cristina Messa; Cristina Colombo; Rosa Maria Moresco; Clara Gobbo; Laura Galli; Giovanni Lucignani; Maria Carla Gilardi; Giovanna Rizzo; Enrico Smeraldi; Raffaella Zanardi; Francesc Artigas; Ferruccio Fazio
Journal:  Psychopharmacology (Berl)       Date:  2003-03-11       Impact factor: 4.530

9.  Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study.

Authors:  M Reimold; A Batra; A Knobel; M N Smolka; A Zimmer; K Mann; C Solbach; G Reischl; F Schwärzler; G Gründer; H-J Machulla; R Bares; A Heinz
Journal:  Mol Psychiatry       Date:  2008-02-12       Impact factor: 15.992

10.  Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey.

Authors:  Michael R Phillips; Jingxuan Zhang; Qichang Shi; Zhiqiang Song; Zhijie Ding; Shutao Pang; Xianyun Li; Yali Zhang; Zhiqing Wang
Journal:  Lancet       Date:  2009-06-13       Impact factor: 79.321

View more
  3 in total

Review 1.  Transpathology: molecular imaging-based pathology.

Authors:  Mei Tian; Xuexin He; Chentao Jin; Xiao He; Shuang Wu; Rui Zhou; Xiaohui Zhang; Kai Zhang; Weizhong Gu; Jing Wang; Hong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-13       Impact factor: 9.236

2.  A case of recurrent depressive disorder presenting with Alice in Wonderland syndrome: psychopathology and pre- and post-treatment FDG-PET findings.

Authors:  Tatsushi Yokoyama; Tsuyoshi Okamura; Miwako Takahashi; Toshimitsu Momose; Shinsuke Kondo
Journal:  BMC Psychiatry       Date:  2017-04-27       Impact factor: 3.630

3.  PET Demonstrates Functional Recovery after Treatment by Danhong Injection in a Rat Model of Cerebral Ischemic-Reperfusion Injury.

Authors:  Zefeng Wang; Fahuan Song; Jinhui Li; Yuyan Zhang; Yu He; Jiehong Yang; Huifen Zhou; Tao Zhao; Wei Fu; Panke Xing; Haitong Wan; Mei Tian; Hong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-23       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.